Other Events ·
On August 7, 2026, Wave Life Sciences completed a redomiciliation from Singapore to Delaware via a statutory scheme of…
WVEWave Life Sciences, Inc.
On August 7, 2026, Wave Life Sciences completed a redomiciliation from Singapore to Delaware via a statutory scheme of arrangement. All issued ordinary shares of the former Singapore parent were exchanged on a one-for-one basis for newly issued common stock of the new Delaware parent, Wave Life Sciences, Inc. The Singapore entity became a wholly owned subsidiary and its shares will be delisted from Nasdaq prior to August 10, 2026. Trading in the new Delaware common stock under symbol 'WVE' begins on that date. Existing directors and executive officers assumed their roles in the new entity, and equity incentive plans were amended and restated to reference Delaware shares. The company operates in the biotechnology industry, focusing on the discovery and development of small molecule therapeutics.